My faith in the FDA has been shaken over the last year. The drug aducanamab
ADUHELM, the New Treatment for Alzheimer's and Dementia | Infusion For Health
was okayed by the FDA for Alzheimers. This was done despite any evidence for clinical effectiveness. A number of the people on the panel reviewing the drug resigned in protest.
Like many things in our society money can corrupt institutions that we would assume were incorruptible. The way officials can bounce between government and private industry and back is worrisome. This issue has been seen in the military when it comes to deciding on weapon systems. But I think it is creeping in at the FDA.
To my eyes the ONYX data was not compelling about using low INR for their valves but the FDA cleared it. Personally to me the downside of an embolism is much worse then extra bleeding at an INR of 3 vs 2. Since it has been mentioned many times if you aim for 1.5 you could easily hit 1.2.